Every 424B that FibroBiologics, Inc. (FBLG) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow FBLG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FBLG filings page.
FibroBiologics, Inc. is registering for resale up to 12,530,613 shares of common stock issuable from June 2026 private‑placement warrants, including Pre-Funded, Short-term, Long-term and placement agent warrants. Existing investors, not the company, will sell these shares from time to time.
FibroBiologics will not receive proceeds from stockholder resales but may obtain up to approximately $6.3 million in gross proceeds if the June Warrants are exercised for cash. Common stock outstanding was 6,080,560 shares as of July 8, 2026, rising to 18,611,173 shares if all such warrants are exercised.
The company recently executed a 1-for-20 reverse stock split, completed an April 2026 equity offering with approximately $2.5 million in net proceeds, and established a $7.5 million at-the-market program, while regaining Nasdaq bid-price and equity listing compliance subject to one-year monitoring periods.
FibroBiologics filed a prospectus supplement updating its at‑the‑market sales capacity under the Form S-3 registration: it may sell up to $7,500,000 of Common Stock from time to time through H.C. Wainwright & Co. The supplement states the company sold approximately $8.14 million of Common Stock in the prior 12 months and sold about $0.17 million under the earlier supplement. The company reports a public float of approximately $47.0 million based on 5,399,112 shares held by non‑affiliates as of May 5, 2026, and notes Nasdaq closing prices of $1.38 (May 4, 2026) and $8.70 (March 6, 2026) used in float calculation. The offering is subject to the Form S-3 General Instruction I.B.6 limitations and the Sales Agreement, with any additional sales requiring a new prospectus supplement.
FibroBiologics is offering up to $6,150,000 of its common stock in an at‑the‑market offering under a Sales Agreement with H.C. Wainwright & Co., allowing sales from time to time on Nasdaq at prevailing market prices. The company completed a 1-for-20 reverse stock split effective March 30, 2026, and reported 5,208,915 shares outstanding prior to this offering. The Sales Agreement pays a 3.0% sales commission to Wainwright; net proceeds, timing and the number of shares sold will vary with market prices. The prospectus notes the company’s public float calculation and Nasdaq listing compliance steps and discloses that the April registered offering generated approximately $2.5M in net proceeds.
FibroBiologics is offering 1,028,788 shares of common stock, 1,243,940 pre-funded warrants and accompanying warrants to purchase up to 2,272,728 shares, at a combined public offering price of $1.32 per share plus warrant. Each public Warrant has an exercise price of $1.32 and is exercisable only after the effective date of the Warrant Stockholder Approval. Pre-Funded Warrants are exercisable for $0.00001 per share and are issued to limit single‑holder ownership above 4.99% (or electively 9.99%). The offering contemplates Placement Agent compensation including 159,091 Placement Agent Warrants and assumes delivery in a single closing. The prospectus gives effect to a 1-for-20 reverse stock split effective March 30, 2026, and states estimated net proceeds of approximately $2.5 million assuming full cash exercise of the Pre-Funded Warrants. The company remains listed on Nasdaq under FBLG and is taking these actions while seeking to regain compliance with Nasdaq bid-price requirements.
FibroBiologics, Inc. is offering 5,227,275 shares of common stock at $0.33 per share in a registered direct offering to institutional investors, for gross proceeds of about $1.7 million and estimated net proceeds of roughly $1.5 million.
Each share is sold together with a warrant, in a concurrent unregistered private placement, to buy one additional share at $0.33, for up to 5,227,275 warrant shares. These warrants become exercisable only if stockholders approve the underlying share issuance and would expire five years after that approval.
The company plans to use the cash for working capital and general corporate purposes but states it will still need additional financing in the future to continue as a going concern. Recent November 2025 equity financings and the cash redemption of a $3.4 million convertible note have added new shares and warrants, while extensive outstanding derivative securities and current Nasdaq bid-price and market-value deficiency notices underscore dilution and listing-risk concerns.
FibroBiologics, Inc. is registering 4,477,614 shares of common stock in a primary offering at $0.335 per share, raising gross proceeds of about $1.5 million and estimated net proceeds of approximately $1.2 million after fees. In a concurrent but separate private placement, investors also receive unregistered warrants on a one-for-one basis with a $0.335 exercise price, which become exercisable only if stockholders later approve the underlying warrant shares. The company plans to use the cash for working capital and general corporate purposes, but warns it will still need additional financing to continue as a going concern. New buyers face immediate dilution, and future exercises of options, warrants and convertible notes could further expand the share count. FibroBiologics also discloses Nasdaq notices for failing the $1.00 bid-price and $35 million market-value listing standards, creating a risk that its stock could be delisted if compliance is not regained.
FibroBiologics, Inc. is conducting a primary offering of 3,540,000 shares of common stock and pre-funded warrants to purchase up to 8,570,203 shares of common stock, together with the shares issuable upon exercise of those pre-funded warrants. The securities are sold to a single investor at $0.3303 per share (or $0.33029 per pre-funded warrant) and paired with privately placed warrants to purchase up to 12,110,203 additional shares, exercisable at $0.3303 per share if stockholders approve the related share issuance.
Payment for the common stock and pre-funded warrants will be made in 983 one-ounce sovereign-issued .9999 fine gold coins valued at $4,069.18 per ounce, which the company plans to liquidate into cash. Net proceeds are estimated at about $3.9 million and are expected to be used for general corporate purposes, including repayment of debt under a $15 million Standby Equity Purchase Agreement, where $3.4 million principal remained on the third note before redemption.
The company warns that it will still require additional financing to continue as a going concern and highlights potential dilution from derivative securities. It also discloses Nasdaq Capital Market listing deficiencies related to minimum bid price and market value of listed securities, noting that failure to regain compliance could lead to delisting and reduced liquidity for its common stock.